Riskpilot← Back to searchSign inGet full accessGLUCOSET AS
ASActiveOrg 997780922Gaustadalléen 21, 0349 OsloAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 201213 employeeswww.glucoset.com
Revenue 2024
NOK 0
EBITDA margin
—
+1% vs 2023
Equity ratio
90.1%
Financial strength
Net profit 2024
NOK -5M
+23% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -5,3M | +1% |
| Net profit | NOK -5M | +23% |
| Total assets | NOK 85,1M | +15% |
| Equity | NOK 76,7M | +19% |
| Employees | 13 | — |
Legal name
GLUCOSET AS
Org number
997780922
Legal form
Aksjeselskap
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
18. januar 2012
Share capital
NOK 1 379 620
Employees
13 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Medisinsk diagnostikk og virksomhet forbundet med dette.
Address
Gaustadalléen 21, 0349 Oslo
Phone
+4797789077
Email
post@glucoset.com
Website
www.glucoset.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200 | 838 | 1 743 | 1 602 | 2 138 | 296 | 0 | 22 | 190 | 900 | 0 | 350 | 0 |
| Staff expenses | −388 | −519 | −776 | −1 720 | −1 038 | −939 | −1 420 | −10 967 | −13 555 | −14 292 | −15 125 | −16 456 | −21 421 |
| EBITDA | −521 | −150 | 280 | −1 803 | −281 | −2 346 | −3 249 | −4 078 | −2 305 | −982 | −4 219 | −5 322 | −5 293 |
| Depreciation & amort. | −9 | −12 | −12 | −12 | −12 | −3 | −91 | −308 | −421 | −732 | −371 | −259 | −106 |
| EBIT | −530 | −162 | 267 | −1 815 | −293 | −2 349 | −3 340 | −4 386 | −2 726 | −1 714 | −4 590 | −5 582 | −5 399 |
| Net financials | 0 | 0 | 1 | −7 | 4 | −50 | −145 | −204 | −236 | −779 | −1 173 | −941 | 369 |
| Profit before tax | −530 | −162 | 268 | −1 822 | −289 | −2 399 | −3 485 | −4 589 | −2 962 | −2 493 | −5 762 | −6 523 | −5 030 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −530 | −162 | 268 | −1 822 | −289 | −2 399 | −3 485 | −4 589 | −2 962 | −2 493 | −5 762 | −6 523 | −5 030 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 614 | 930 | 1 512 | 2 929 | 4 552 | 8 374 | 28 200 | 28 104 | 26 758 | 35 793 | 49 165 | 74 030 | 85 083 |
| Equity | 457 | 295 | 821 | −1 001 | 1 710 | 2 457 | 16 226 | 17 401 | 22 767 | 20 731 | 15 453 | 64 294 | 76 693 |
| Long-term debt | 0 | 0 | 415 | 1 500 | 1 500 | 1 070 | 985 | 985 | 985 | 7 849 | 14 951 | 4 180 | 3 595 |
| Short-term debt | 156 | 220 | 277 | 1 545 | 457 | 3 862 | 10 989 | 9 718 | 3 007 | 7 213 | 18 760 | 5 556 | 4 795 |
| Total debt | 156 | 220 | 692 | 3 045 | 1 957 | 4 932 | 11 974 | 10 703 | 3 992 | 15 063 | 33 712 | 9 736 | 8 390 |
EBITDA margin
-529333500.0%
This company
15.8%
Market median
-3350212125% vs market
20122024
Equity ratio
90.1%
This company
38.2%
Market median
+136% vs market
20122024
Return on equity
-6.6%
This company
18.4%
Market median
-136% vs market
20122024
Net profit margin
-502951400.0%
This company
8.1%
Market median
-6209276643% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20122024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Deputy Member | Deputy Member | 2023 | — | — |
NL Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
JA Deputy Member | Deputy Member | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Eic Fund, Sicaav-Raif, Swiss Diabet | Company | 27.9% | 27.9% | 2023 |
Norsk Innovasjonskapital Iv As | Company | 19.8% | 19.8% | 2024 |
Eic Fund, Sicaav-Raif | Company | 19.5% | 19.5% | 2024 |
Swiss Diabetes Venture Fund Scsp, S | Company | 15.6% | 15.6% | 2024 |
Mp Pensjon Pk | Company | 6.7% | 6.7% | 2024 |
Anelsen As | Company | 6.5% | 6.5% | 2024 |
Sweet Spot Holding As | Company | 2.8% | 2.8% | 2024 |
| Individual | 2.6% | 2.6% | 2024 | |
Molver As | Company | 2.1% | 2.1% | 2024 |
Fh Holding 2 As | Company | 1.6% | 1.6% | 2024 |
| Individual | 1.6% | 1.6% | 2024 | |
Thress As | Company | 1.4% | 1.4% | 2024 |
Helseleverandøren As | Company | 1.3% | 1.3% | 2023 |
Oseng As | Company | 1.3% | 1.3% | 2024 |
Instrat As | Company | 1.2% | 1.2% | 2024 |
Helseleverandøren Holding As | Company | 1.2% | 1.2% | 2024 |
Vesoldo As | Company | 1.1% | 1.1% | 2024 |
| Individual | 1.1% | 1.1% | 2022 | |
| Individual | 1.0% | 1.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GLUCOSET AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Simon Schwaighofer | Deputy Member | 0 companies |
| Nicolas-Andreas Lønvik Elvemo | Chief Executive Officer | 0 companies |
| Jørgen Andre Nilsen | Deputy Member | 0 companies |
| Reinold Ellingsen | Board of Directors | 0 companies |
| Jan Pareli Sollid | Chairman | 0 companies |
| Erik Fuglseth | Board of Directors | 0 companies |
| Trude Tingvoll | Board of Directors | 0 companies |
| Dag Terje Rian | Board of Directors | 0 companies |
| Rune Sørum | Board of Directors | 0 companies |
| Craig Russell Cooper | Board of Directors | 0 companies |